
AdvaMed Advocates for Medtech-Centered Privacy Protections
In response to the House Energy & Commerce Committee Privacy Working Group’s Request for Information, AdvaMed outlines how federal privacy legislation must account for the unique nature of medical device data. This public comment highlights the critical distinctions between clinician-operated medtech and consumer health data tools, and calls for a tailored, innovation-friendly approach to protecting patient privacy while enabling life-saving technologies.
Related Reading
News / Coverage & Payment / Digital Health / Government & Legislative Affairs
AdvaMed Welcomes Introduction of Access to Prescription Digital Therapeutics Act
May 22, 2025
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Legal
OMB Request for Information on Deregulation
May 14, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Legal
AdvaMed® Medical Device Mass Tort TV Ad Trend – Q1 2025
May 13, 2025
Event / Digital Health / research & policy papers
Gaining Financial Commitments in Uncertain Times
June 17th, 2025 12:00 PM – 1:00 PM ET
Join Sunrise Labs in discussion of how in today’s climate of economic uncertainty, regulatory complexity, and constrained capital markets, securing investor funding is more challenging—and more vital—than ever for medtech companies. This executive-level webinar brings together seasoned leaders from across the medtech ecosystem to share proven strategies for building investor confidence and driving funding decisions. The session will offer actionable insights into how to communicate value, navigate risk, and chart a clear path from vision to viability.
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Releases “AI Policy Roadmap” to Guide Congress and Federal Agencies
April 22, 2025
Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the next era of artificial intelligence-enabled medical and digital health technologies to provide patients and clinicians transformative new tools to aid in diagnosis and treatment.
News / Diagnostics / Digital Health
Satio, Nanowear announce partnership offering first, holistic, home-based in vivo- + in vitro diagnostics + drug delivery
April 15, 2025
BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ — Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear’s at-home AI-based nanotechnology biomarker diagnostic platform with Satio’s at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk assessment.
Event / Code of Ethics / Legal
MedTech Compliance Bootcamp
September 16, 2025 | 8:00 AM – 6:30 PM
September 17, 2025 | 8:00 AM – 2:00 PM
Join AdvaMed & Porzio for this comprehensive compliance bootcamp to better understand the current medtech compliance framework.
News / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs
Bipartisan Health Tech Investment Act Will Enhance Patient Access to AI-Enabled Medical Devices
April 10, 2025
WASHINGTON – AdvaMed, the Medtech Association, today commended Senators Mike Rounds (R-SD) and Martin Heinrich (D-NM) for introducing the Health Tech Investment Act (S. 1399). This landmark bipartisan legislation will establish a stable reimbursement pathway for medical devices authorized by the U.S. Food & Drug Administration (FDA) that rely on artificial intelligence (AI) and machine learning (ML), also known as Algorithm-Based Healthcare Services (ABHS).